Ovarian Hyperstimulation Syndrome
A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.
Drugs by status
Phase 4 trials (13)
Phase 3 trials (5)
Phase 2 trials (7)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (13)
Organization Involved with Phase 3 Indications (13)
- GeneScience Pharmaceuticals Co., Ltd.
- Central South University
- Benha University
- KK Women's and Children's Hospital
- Nanjing Medical University
- National Yang-Ming University
- University of Valencia
- Peking University
- Taichung Veterans General Hospital
- Zhejiang University
- Anhui College of Traditional Chinese Medicine
- Taipei Veteran General hospital
- Inner Mongolia Medical University
Organization Involved with Phase 2 Indications (6)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (11)
- Schering-Plough
- University of London
- Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
- Virginia Center for Reproductive Medicine
- Yale University
- Southern Medical University
- Government of China
- Rize University
- National Natural Science Foundation of China
- Guangzhou Science and Technology Program key projects
- National Key Basic Research Development Plan of China